Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)

NCT07550920 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Drug: Retlirafusp alfa
DRUG: Drug: Single-agent Chemotherapy
OTHER: Procedure: Radical Surgery

Sponsor

Tianjin Medical University Cancer Institute and Hospital